

Rheumatic Fever And RHD

Dr. Abdulelah Mobeirek (FRCPC)

Consultant Cardiologist KFCC

Lecture Outline


- ❑ What is ARF And RHD?
- ❑ Diagnosis
- ❑ Jones Criteria & 2015 revision
- ❑ Differential Diagnosis
- ❑ Investigations, Management
- ❑ Rheumatic Valvular Heart Disease
- ❑ Prevention

Rheumatic Fever

- ❑ Follows group A beta hemolytic streptococcal throat infection
- ❑ It represents a delayed immune response to infection with manifestations appearing after a period of 2-4 weeks
- ❑ Age 5-15 yrs
- ❑ A multisystem disease
- ❑ RHD is a long term complication of ARF
- ❑ Major effect on health is due to damage to heart valves

Pathologic Lesions

- ❑ Ashcoff nodules
- ❑ Fibrinoid degeneration of connective tissue, inflammatory cells



Global Burden of RHD

- ❑ A leading cause of CV morbidity & mortality in young people
- ❑ Total cases with RHD: 20 Millions
- ❑ CHF: 3 Million, valve surgery required in 1 Million
- ❑ Annual incidence of RF: 0.5 Million, nearly half develop carditis
- ❑ Estimated deaths from RHD: 250,000/YR
- ❑ Imposes a substantial burden on health care systems with limited budgets

Epidemiologic Background

- ❑ The incidence of RF and the prevalence of RHD has declined substantially in Europe, North America and other developed nations
- ❑ this decline has been attributed to improved hygiene, reduced household crowding, and improved medical care

Epidemiologic Background

- ❑ The major burden is currently found in low and middle income countries (India, middle east), and in selected indigenous populations of certain developed countries (Australia and Newzealand).
- ❑ A disease of poverty and low socioeconomic status
- ❑ In underdeveloped countries RHD is the leading cause of CV death during the first five decades of life

Epidemiologic Background

- The incidence in indigenous population of Australia: 53-380 cases/100000 people/yr in 5-14 yrs age group.
- In Saudi Arabia: incidence 30 cases/100000 people/yr and prevalence 310/100000 people in 6-15 yrs age group
- Low risk population ARF incidence < 2/100000/yr (5-14 yrs) or all age prevalence of RHD <1/1000 population/yr

Diagnosis of ARF

- ❑ No single test to diagnose ARF
- ❑ The symptoms and signs are shared by many inflammatory and infectious diseases
- ❑ Accurate diagnosis is important
- ❑ Overdiagnosis will result in individuals receiving treatment unnecessarily
- ❑ Underdiagnosis may lead to recurrences of ARF causing further damage, the need for valve surgery, CHF and premature death

Diagnosis of ARF

- ❑ Diagnosis is primarily clinical and is based on a constellation of signs and symptoms, which were initially established as the Jones criteria
- ❑ In 1944 Dr. TD Jones published a set of guidelines for diagnosis of ARF “Jones Criteria”
- ❑ Subsequently Modified in 1965, 1984 and 1992 by AHA
- ❑ Revised recently -2015 by AHA

1992 Modified Jones Criteria

Major criteria	Minor criteria
Migratory polyarthritits	Arthralgia
Carditis	Fever
Erythema marginatum	First degree heart block
Syndenham chorea	Elevated inflammatory markers (ESR, CRP)
Subcutaneous nodules	

Carditis

- ❑ Occurs in 50-70% of cases
- ❑ Only manifestation of ARF that leaves permanent damage
- ❑ May be subclinical
- ❑ Murmurs of MR or AR may occur in acute stage while mitral stenosis occurs in late stages
- ❑ Cardiomegaly and CHF may occur

Arthritis

- ❑ Common: present in 35-66%
- ❑ Earliest manifestation of ARF
- ❑ Large joints: The knees and ankles, shoulders, elbows
- ❑ “Migrating”, “Fleeting” polyarthrititis
- ❑ Duration short < 1 week
- ❑ Rapid improvement with salicylates
- ❑ Does not progress to chronic disease

Sydenham Chorea

- ❑ Also known as Saint Vitus' dance
- ❑ Occur in 10-30%, extrapyramidal manifestation, female predominance
- ❑ Abrupt Purposeless involuntary movements of muscles of face, neck, trunk, and limbs.
- ❑ Delayed manifestation of ARF - months
- ❑ Clinically manifest as-clumsiness, deterioration of handwriting, emotional lability or grimacing of face

Subcutaneous Nodules

- ❑ Occur in 10%
- ❑ Usually 0.5 – 2 cm long
- ❑ Firm non-tender
- ❑ Occur over extensor surfaces of joints, on bony prominences, tendons, spine
- ❑ Short lived: last for few days
- ❑ Associated with severe carditis

Subcutaneous nodules



Subcutaneous Nodules



Erythema Marginatum

- ❑ Present in <6%
- ❑ Less common, but highly specific manifestation of ARF
- ❑ Reddish border, pale center, round or irregular serpiginous borders, non-pruritic, transient rash
- ❑ Occurs on trunk, abdomen or proximal limbs
- ❑ Associated with carditis

Erythema Marignatum



2015 Revised Jones Criteria

Revision of the Jones Criteria for the Diagnosis of Acute Rheumatic Fever in the Era of Doppler Echocardiography

A Scientific Statement From the American Heart Association

Circulation. published online April 23, 2015;

2015 Revision of Jones Criteria

1. In accordance with the degree of **prevalence** of ARF/RHD in the population:
 - ❑ **low risk populations** have been defined as those with ARF incidence $< 2:100000$ school-age children or all age prevalence of RHD of $< 1:1000$ population per year
 - ❑ Children not from low risk population have been considered to be at **moderate or high risk**

2015 Revision of Jones Criteria

2. Advocated the use of **Echocardiography** in all cases of confirmed or suspected ARF or RHD, to diagnose valvulitis(subclinical carditis) and has been included as a **major criterion to diagnose carditis**

3. Aseptic **monoarthritis** has been included as a **major criteria** in moderate or high risk population

2015 Revision of Jones Criteria

4. **Polyarthriti**s has been recognized as a major manifestation for **moderate or high risk population**

5. **Fever** >38.5 c, ESR >60 and or CRP > 3mg/dl for low risk population, and fever >38 and ESR >30 and or CRP > 3mg/dl for moderate or high risk population

Revised Jones Criteria-2015

A. For all patient populations with evidence of preceding GAS infection

Diagnosis: initial ARF

2 Major manifestations or 1 major plus 2 minor manifestations

Diagnosis: recurrent ARF

2 Major or 1 major and 2 minor or 3 minor

B. Major criteria

Low-risk populations*

Carditis†

- Clinical and/or subclinical

Arthritis

- Polyarthritis only

Chorea

Erythema marginatum

Subcutaneous nodules

Moderate- and high-risk populations

Carditis

- Clinical and/or subclinical

Arthritis

- Monoarthritis or polyarthritis
- Polyarthralgia‡

Chorea

Erythema marginatum

Subcutaneous nodules

C. Minor criteria

Low-risk populations*

Polyarthralgia

Fever ($\geq 38.5^{\circ}\text{C}$)

ESR ≥ 60 mm in the first hour and/or CRP ≥ 3.0 mg/dL§

Prolonged PR interval, after accounting for age variability (unless carditis is a major criterion)

Moderate- and high-risk populations

Monoarthralgia

Fever ($\geq 38^{\circ}\text{C}$)

ESR ≥ 30 mm/h and/or CRP ≥ 3.0 mg/dL§

Prolonged PR interval, after accounting for age variability (unless carditis is a major criterion)

2015 Revised Jones Criteria

A firm **diagnosis** requires

1) 2 Major manifestations or 1 Major and 2 Minor manifestations

and

2) Evidence of a recent streptococcal infection.

2015 Revised Jones Criteria

Evidence of Preceding GAS Infection:

- 1) Increased or rising ASO titer or Anti-Dnase B titer
- 2) A positive throat culture

Rheumatic Fever Recurrences

- Reliable past history of ARF: 2 major or 1 major and 2 minor or 3 minor manifestations sufficient for diagnosis
- Presence of antecedent streptococcal infection
- When minor manifestations only present exclude other causes.

DDX of ARF

Presentation		
Polyarthrititis and fever	Carditis	Chorea
Septic arthritis (including disseminated gonococcal infection) [†]	Innocent murmur	Systemic lupus erythematosus
Connective tissue and other autoimmune disease ^{††}	Mitral valve prolapse	Drug intoxication
Viral arthropathy [‡]	Congenital heart disease	Wilson's disease
Reactive arthropathy [‡]	Infective endocarditis	Tic disorder [‡]
Lyme disease [‡]	Hypertrophic cardiomyopathy	Choreoathetoid cerebral palsy
Sickle cell anaemia	Myocarditis: viral or idiopathic	Encephalitis
Infective endocarditis	Pericarditis: viral or idiopathic	Familial chorea (including Huntington's)
Leukaemia or lymphoma		Intracranial tumour
Gout and pseudogout		Lyme disease [‡]
		Hormonal [§]

Investigations

Recommended for all cases

White blood cell count

Erythrocyte sedimentation rate (ESR)

C-reactive protein (CRP)

Blood cultures, if febrile

Electrocardiogram (if prolonged P-R interval or other rhythm abnormality, repeat in 2 weeks and again at 2 months, if still abnormal)

Chest X-ray, if clinical or echocardiographic evidence of carditis

Echocardiogram (consider repeating after 1 month, if negative)

Throat swab (preferably before giving antibiotics): culture for group A streptococcus

Antistreptococcal serology: both ASO and anti-DNase B titres, if available (repeat 10–14 days later if first test not confirmatory)

Investigations

Investigations in suspected ARF

All patients with suspected or confirmed ARF should undergo echocardiography to confirm or refute the diagnosis of rheumatic carditis.

Treatment of ARF

- Bed rest
- Salicylates : Aspirin
 - 75-100 mg /kg/day given as 4 divided doses for 6 -8 weeks
 - Attain a blood level 20-30 mg/dl
- Penicillin: Procaine Penicillin 4 million units/day x10 days
- Prednisolone: 2mg/kg/day taper over 6 weeks, Given when there is severe carditis
- Heart Failure Treatment: diuretics, ACEI


Chronic Rheumatic Heart Disease

- ❑ Most commonly in Mitral-70%
- ❑ Frequently in Aortic-40%
- ❑ Less frequently Tricuspid-10%
- ❑ Rarely pulmonary valve-2%
- ❑ Mitral Stenosis is more common in females(3:1), while males have higher incidence of Aortic Regurgitation

Mitral Stenosis

- ❑ The normal MVA = 4-5 cm²
- ❑ In severe ms < 1.5 cm²
- ❑ High LAP
- ❑ The rise in LAP causes a similar rise in pulmonary capillaries, veins and artery

Mitral Stenosis



Clinical Features

- ❑ Dyspnea
- ❑ Fatigue
- ❑ Palpitation
- ❑ Hemoptysis (10%)
- ❑ Hoarseness (Ortner's syndrome)
- ❑ Dysphagia
- ❑ Stork or peripheral embolization

Clinical Features

- ❑ Cyanosis (Mitral facies, malar flush)
- ❑ Tapping apex (S1)
- ❑ Parasternal heave
- ❑ Diastolic thrill
- ❑ Accentuated S1 , accentuated S2
- ❑ Opening snap
- ❑ Mid-diastolic rumble

Investigations


□ CXR

- Straightening of the left heart border
- Double density
- Kerley B lines , CA in MV

□ ECG: LAE, P Mitrale ,RV dominance

□ Echodoppler


Echo In Mitral Stenosis



Management

- ❑ B-Blockers ,CCB
- ❑ Digoxin (AF)
- ❑ Warfarin
- ❑ Balloon Valvuloplasty
- ❑ Mitral valve replacement


BMV



Mitral Regurgitation

- ❑ Asymptomatic
- ❑ Dyspnea , orthopnea, PND
- ❑ Displaced PMI, Thrill
- ❑ Soft S1,
- ❑ Pansystolic murmur
- ❑ Treatment is surgical


ECHO




Aortic Regurgitation

- ❑ Water-hammer / collapsing pulse
- ❑ Wide pulse pressure
- ❑ Corrigan's sign
- ❑ De Musset sign
- ❑ Muller sign
- ❑ Quincke's pulse
- ❑ Hill's sign

ECHO



Aortic Stenosis



Symptoms

- Angina
- Syncope
- Dyspnea

Signs

- Arterial Pulse wave form : Plateau
 - Small (Parvus)
 - Slow rise (Tardus)
- Sustained not displaced PMI
- Systolic thrill
- S4

Signs

- ❑ Late peaking of murmur
- ❑ Single S2 : Soft or absent A2
- ❑ Paradoxical splitting of S2

Aortic Valve Disease

Treatment:

- ❑ Aortic valve Replacement
- ❑ Transcatheter Aortic Valve Replacement

Secondary Prevention of Rheumatic Fever (Prevention of Recurrent Attacks)

Agent	Dose	Mode
Benzathine penicillin G	1 200 000 U every 4 weeks*	Intramuscular
or		
Penicillin V	250 mg twice daily	Oral
or		
Sulfadiazine	0.5 g once daily for patients 27 kg (60 lb) 1.0 g once daily for patients >27 kg (60 lb)	Oral

For individuals allergic to penicillin and sulfadiazine

Erythromycin	250 mg twice daily	Oral
---------------------	---------------------------	-------------

***In high-risk situations, administration every 3 weeks is justified and recommended**

Duration of Secondary Rheumatic Fever Prophylaxis

Category

Duration

Rheumatic fever with carditis and residual heart disease (persistent valvar disease*)

10 y since last episode or until age 40y ,(whichever is longer), sometimes life long prophylaxis

**Rhumatic fever with carditis
But no residual VHD**

**10 yrs or until age 21yrs
(whichever is longer)**

Rheumatic fever without carditis

**5 y or until age 21 y,
(whichever is longer)**
